Usefulness of Transcriptional Blood Biomarkers as a Non-invasive Surrogate Marker of Mucosal Healing and Endoscopic Response in Ulcerative Colitis

• Published in: Journal of Crohn's and colitis Vol. 11; no. 11; pp. 1335 - 1346
• Main Authors: Planell, Núria, Masamunt, M Carme, Leal, Raquel Franco, Rodríguez, Lorena, Esteller, Miriam, Lozano, Juan J, Ramírez, Anna, Ayrizono, Maria de Lourdes Setsuko, Coy, Claudio Saddy Rodrigues, Alfaro, Ignacio, Ordás, Ingrid, Visvanathan, Sudha, Ricart, Elena, Guardiola, Jordi, Panés, Julián, Salas, Azucena
• Format: Journal Article
• Language: English
• Published: England Oxford University Press 27-10-2017
• Subjects: Adult; Biomarkers - blood; Colitis, Ulcerative - blood; Colitis, Ulcerative - diagnosis; Colitis, Ulcerative - pathology; Colon - pathology; Colonoscopy; Female; Humans; Intestinal Mucosa - pathology; Male; Middle Aged; Oligonucleotide Array Sequence Analysis; Original; Real-Time Polymerase Chain Reaction; Treatment Outcome; ulcerative colitis; blood biomarkers; Gene expression; anti-TNF-α
• ISSN: 1873-9946; 1876-4479
• DOI: 10.1093/ecco-jcc/jjx091

Ulcerative colitis [UC] is a chronic inflammatory disease of the colon. Colonoscopy remains the gold standard for evaluating disease activity, as clinical symptoms are not sufficiently accurate. The aim of this study is to identify new accurate non-invasive biomarkers based on whole-blood transcriptomics that can predict mucosal lesions and response to treatment in UC patients.
Whole-blood samples were collected for a total of 152 UC patients at endoscopy. Blood RNA from 25 UC individuals and 20 controls was analysed using microarrays. Genes that correlated with endoscopic activity were validated using real-time polymerase chain reaction in an independent group of 111 UC patients, and a prediction model for mucosal lesions was evaluated. Responsiveness to treatment was assessed in a longitudinal cohort of 16 UC patients who started anti-tumour necrosis factor [TNF] therapy and were followed up for 14 weeks.
Microarray analysis identified 122 genes significantly altered in the blood of endoscopically active UC patients. A significant correlation with the degree of endoscopic activity was observed in several genes, including HP, CD177, GPR84, and S100A12. Using HP as a predictor of endoscopic disease activity, an accuracy of 67.3% was observed, compared with 52.4%, 45.2%, and 30.3% for C-reactive protein, erythrocyte sedimentation rate, and platelet count, respectively. Finally, at 14 weeks of treatment, response to anti-TNF therapy induced alterations in blood HP, CD177, GPR84, and S100A12 transcripts that correlated with changes in endoscopic activity.
Transcriptional changes in UC patients are sensitive to endoscopic improvement and appear to be an effective tool to monitor patients over time.